Drug Approval | July 11, 2023
NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData
Approval to dramatically change CAR-T therapies landscape
Approval to dramatically change CAR-T therapies landscape
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
